Intraperitoneal adjuvant immunochemotherapy in operable XXXX with serosal involvement.

@entity1 @entity3003 @entity900 @entity1295 @entity1753 @entity2879 @entity490 @entity204 @entity356
Since the peritoneal cavity is the most common site of initial recurrence in @entity1 after surgery for @entity356 , an intraperitoneal (IP) adjuvant treatment was tested in @entity1 with resected @entity356 with serosal involvement. Between March 1986 and September 1991, 44 consecutive @entity1 with resected T3/T4-N0/N+ @entity356 were given an IP combination, including @entity900 or @entity3003 , @entity2879 , and alpha interferon-2b. The overall survival of these @entity1 was compared with that observed in 47 historical controls (admitted to the same institutions from 1983 to 1986) with similar prognostic characteristics, who had not received adjuvant treatment after surgery. No major complication relating to the IP route was observed. Mild to moderate @entity490 occurred in nine @entity1 . Grade 3-4 myelotoxicity occurred in 14 @entity1 . Interferon had to be reduced in five @entity1 and suspended in one because of severe @entity1295 . Emesis occurred in 23/28 @entity1 given @entity900 and 9/16 given @entity3003 . At the time of this analysis (September 1992) median follow-up was 42 months (range 12-78) in the group receiving IP treatment, and 97 months (range 74-128) in the historical controls. There had been 20 @entity204 among treated @entity1 compared with 36 in the control group. The 5-year estimated survival rate was significantly better in the @entity1 who received IP adjuvant treatment (44% +/- 9 versus 23% +/- 6; P = 0.016). Using the Cox proportional hazard model with a backward procedure to correct for the influence of prognostic pretreatment variables, IP treatment again afforded a significant advantage in terms of survival (P = 0.04). @entity1753 immunochemotherapy appears to improve prognosis compared with historical controls in @entity1 having operable @entity356 with serosal infiltration.
